RNAZ vs CLYM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

RNAZ

45.8
AI Score
VS
RNAZ Wins

CLYM

41.5
AI Score

Investment Advisor Scores

RNAZ

46score
Recommendation
HOLD

CLYM

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNAZ CLYM Winner
Net Income -24.54M -41.79M RNAZ
Operating Income -24.54M -47.46M RNAZ
ROE 88.6% -18.3% RNAZ
ROA -16.2% -17.7% RNAZ
Total Assets 151.01M 236.56M CLYM
Cash 8.38M 39.73M CLYM
Current Ratio 1.97 26.58 CLYM
Free Cash Flow -10.39M -38.01M RNAZ

Relative Price Performance (Last 90 Days)

RNAZ 1M: -17.0% · 3M: -59.9% CLYM 1M: +19.3% · 3M: -16.5%

Current Technical Phase

RNAZ

Markdown
Sell / avoid

Price below a falling SMA50 (slope -25.5%), weak momentum, RSI 34

RSI (14): 34.4 · Price: $1.40

CLYM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 61.5 · Price: $12.30

Fundamentals Snapshot

Metric RNAZ CLYM
Market Cap — —
Forward P/E -4.2 -12.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — —
Operating Margin 0.0% 0.0%
EPS -52.06 -0.81
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNAZ is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.